Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 11, Issue 11, Pages 1769-1780Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425247.2014.938635
Keywords
drug delivery; microneedle; skin; transdermal; vaccine
Categories
Funding
- BBSRC [BB/K020234/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/K020234/1] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [1347368] Funding Source: researchfish
Ask authors/readers for more resources
Introduction: Transdermal drug delivery offers a number of advantages for the patient, not only due to its non-invasive and convenient nature, but also due to factors such as avoidance of first-pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedles (MNs) can increase the number of compounds amenable to transdermal delivery by penetrating the skin's protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below. Areas covered: MNs have been extensively investigated for drug and vaccine delivery. The different types of MN arrays and their delivery capabilities are discussed in terms of drugs, including biopharmaceutics and vaccines. Patient usage and effects on the skin are also considered. Expert opinion: MN research and development is now at the stage where commercialisation is a viable possibility. There are a number of long-term safety questions relating to patient usage which will need to be addressed moving forward. Regulatory guidance is awaited to direct the scale-up of the manufacturing process alongside provision of clearer patient instruction for safe and effective use of MN devices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available